GABAPENTIN ENACARBIL | N022399 | AZURITY PHARMACEUTICALS INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Public Citizen’s Health Research Group FDA-2022-P-0149 · 9 docket documents Public Citizen submitted this petition on February 9, 2022, under Section 201 of the Controlled Substances Act and FDA regulations requesting that the DEA and FDA initiate proceedings to schedule gabapentin (brand names Neurontin and Gralise) and gabapentin enacarbil (brand name Horizant) into Sched | Other | 2022-02-10 | Denied | Public Citizen’s Health Research Group |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$17.93
per ea
Lowest NADAC/Unit
$17.92
per ea
Brand NDCs
2
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 53451010301HORIZANT ER 300 MG TABLET | $17.93 | EA | Brand | — | 2026-06-17 |
| 53451010101HORIZANT ER 600 MG TABLET | $17.92 | EA | Brand | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.